A prefilled atropine sulfate injection and its production process

Through the control of pH value and high-temperature sterilization technology, the problems of poor oxidation and thermal stability of atropine sulfate injection are solved, and the storage stability and sterility of pre-filled atropine sulfate injection are improved, ensuring that the product complies with the international pharmacopoeia standards.

CN116098859BActive Publication Date: 2024-11-08GRAND PHARMA (CHINA) CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202111326807.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-10
Publication Date
2024-11-08
Estimated Expiration
2041-11-10

AI Technical Summary

Technical Problem

The existing atropine sulfate injection has poor oxidation and thermal stability during the production process, resulting in poor storage stability of pre-filled atropine sulfate injection and excessive impurity content, which cannot meet the international pharmacopoeia standards.

Method used

By controlling the pH value of atropine sulfuric acid in the water for injection to 4.0±0.2, and adopting high-temperature ventilation and dry sterilization, we ensure that the final impurity content and pH value of the product are within the appropriate range, avoiding hydrolysis and high-temperature decomposition, using 0.22μm or Filter the 0.45μm filter element to ensure sterility and airtightness.

Benefits of technology

The storage stability and sterility of pre-filled atropine sulfate injection have been improved, the impurity content is reduced, and it complies with the standards of China, the United States, Japan and Europe to ensure reliable long-term storage quality of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention discloses a prefilled atropine sulfate injection and a production process thereof, comprising the following steps: dissolving atropine sulfate and sodium chloride in water for injection at a temperature of less than 35°C according to the prescribed amount to obtain a drug solution; controlling the pH value to be 4.0±0.2 during the dissolution of atropine sulfate; filtering the drug solution and filling it into a prefilled syringe; placing the prefilled syringe filled with the drug solution in a ventilated drying sterilizer at 115-121°C for sterilization for 8-30 minutes to obtain a final product. On the one hand, the present invention controls the pH value in the process of preparing the drug solution to avoid the ester bond structure of atropine sulfate being easily hydrolyzed under alkaline conditions; on the other hand, controls the temperature and time during the high-temperature sterilization process to avoid high-temperature decomposition to produce impurities, stabilizes the impurity content and pH value of the final product within a certain range, and enables the product to still meet the standard requirements after long-term storage.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of prefilled syringes, and in particular to a prefilled atropine sulfate injection and a production process thereof. Background Art

[0002] Atropine sulfate injection may be oxidized during the production process. The tightness of the syringe directly affects the residual oxygen content of the liquid medicine, which in turn affects the stability of the solution and the level of impurities, affecting the product quality. Prefilled atropine sulfate injection is a prefilled syringe that directly fills the atropine sulfate injection. It can be directly injected when used, and has the advantages of convenient and fast use, accurate dosage, and no cross contamination or secondary contamination.

[0003] The existing common atropine sulfate injection process adopts the circulating steam method for sterilization, the thermal stability of the product is poor, and the prepared liquid does not meet the requirements of pre-filled atropine sulfate injection for impurities. Therefore, the storage stability of common atropine sulfate injection is of little reference value. Although the existing pre-filled atropine sulfate injection has a low impurity content after preparation, it has poor storage stability and the impurities will still exceed the standard after long-term storage. Summary of the invention

[0004] In order to solve the problem of poor storage stability of prefilled atropine sulfate injection, the present invention improves the production process of prefilled atropine sulfate injection, and the impurities of the produced prefilled atropine sulfate injection can still meet the requirements of Chinese Pharmacopoeia (CP), United States Pharmacopoeia (USP), Japanese Pharmacopoeia (JP) and European Pharmacopoeia (EP) after long-term storage.

[0005] In a first aspect, the present invention provides a production process for a prefilled atropine sulfate injection, the production process comprising the following steps:

[0006] Dissolve atropine sulfate and sodium chloride in water for injection at a temperature of less than 35°C according to the prescribed amount to obtain a drug solution; during the dissolution of atropine sulfate, control the pH to be 4.0±0.2;

[0007] Filter the liquid medicine and fill it into a prefilled syringe;

[0008] The prefilled syringe filled with the drug solution is placed in a ventilated dry sterilizer at 115-121°C for sterilization for 8-30 minutes to obtain the final product.

[0009] As a preferred embodiment of the above technical solution, the prescription of the prefilled atropine sulfate injection is: atropine sulfate 0.5 mg / mL, sodium chloride 8.5-9.5 mg / mL.

[0010] As a preferred embodiment of the above technical solution, the prescription of prefilled atropine sulfate injection is: atropine sulfate 0.5 mg / mL, sodium chloride 9.0 mg / mL.

[0011] As a preferred embodiment of the above technical solution, the pH value is controlled at 4.0±0.1 during the dissolution of atropine sulfate.

[0012] As a preferred embodiment of the above technical solution, during the dissolution of atropine sulfate, the pH is controlled to be 4.0±0.1 by dropping dilute sulfuric acid.

[0013] As a preferred embodiment of the above technical solution, the concentration of dilute sulfuric acid is 0.2%.

[0014] As a preferred embodiment of the above technical solution, the prefilled syringe is sterilized in a ventilated dry sterilizer at 121° C. for 12 minutes.

[0015] As a preferred embodiment of the above technical solution, a 0.22 μm or 0.45 μm filter element is used for filtration.

[0016] As a preferred embodiment of the above technical solution, the preparation method of the medicinal solution comprises the following steps:

[0017] Dissolve sodium chloride and atropine sulfate in 95% of the prescribed amount of water for injection;

[0018] Add dilute sulfuric acid to adjust the pH to 4.0 ± 0.2;

[0019] Use the remaining 5% of the prescribed volume of water for injection to make up to volume.

[0020] In a second aspect, the present invention provides a prefilled atropine sulfate injection prepared by the above-mentioned production process of prefilled atropine sulfate injection. Compared with commercially available products, the prefilled atropine sulfate injection has fewer impurities, more stable quality, and a higher level of sterility assurance.

[0021] The present invention has the following advantages and beneficial effects:

[0022] The present invention controls the pH in the process of preparing the liquid medicine to avoid the ester bond structure of atropine sulfate being easily hydrolyzed under alkaline conditions, and controls the temperature in the process of high-temperature sterilization to avoid high-temperature decomposition to produce impurities, thereby stabilizing the impurity content and pH value of the final product within a certain range, so that the product can still meet the requirements of the Chinese Pharmacopoeia (CP), the United States Pharmacopoeia (USP), the Japanese Pharmacopoeia (JP), and the European Pharmacopoeia (EP) after long-term storage. DETAILED DESCRIPTION

[0023] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution of the present invention will be clearly and completely described in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0024] The present invention reduces the impurity content and improves the stability and safety of the product by controlling the pH and high-temperature sterilization temperature in the entire production process, and improves the storage stability of the product by limiting the residual oxygen content of the product and improving the airtightness of the syringe, so that the prefilled atropine sulfate injection meets the standards involved in P1590 of Part II of the 2020 edition of the Chinese Pharmacopoeia.

[0025] The prescription of the prefilled atropine sulfate injection involved in the following examples is: atropine sulfate 0.5 mg / mL, sodium chloride 8.5-9.5 mg / mL; preferably atropine sulfate 0.5 mg / mL, sodium chloride 9.0 mg / mL.

[0026] In the following examples, the temperature of the water for injection is required to be below 35° C. to prevent hydrolysis or oxidation of atropine sulfate during the dissolution process.

[0027] In the following examples, dilute sulfuric acid is used to adjust the pH, preferably dilute sulfuric acid with a concentration of 0.2%.

[0028] In the following embodiments, a polyethersulfone cartridge microporous filter element is used to filter the drug solution; filter element model: 5 inches; technical parameters: polyethersulfone, 0.22 μm / 0.45 μm; manufacturer: Hangzhou Kebet Filter Equipment Co., Ltd.

[0029] In the following examples, a ventilation drying sterilizer is used for sterilization, model RFM-1.2, ≤8400 pieces / cabinet, working pressure: 0.27MPa; design temperature: 144℃; working medium: water vapor; volume: 1.2m 3 ; Shandong Xinhua Medical Instrument Co., Ltd.

[0030] The production process of the prefilled atropine sulfate injection used in the following examples and comparative examples includes the following steps: preparing room temperature injection water, sodium chloride and atropine sulfate according to the prescription amount, dissolving sodium chloride and atropine sulfate in 95% of the prescription amount of room temperature injection water, and stirring for 10 minutes; adding 0.2% dilute sulfuric acid solution to adjust the pH to about 4.0 (allowing fluctuations within the range of 3.8-4.2); using the remaining room temperature injection water to make up to the full amount, stirring for 5 minutes, and obtaining a liquid medicine, at which the pH value is 3.8-4.2; detecting whether the impurity content is qualified: if it is unqualified, subsequent filling and terminal sterilization will not be carried out; if it is qualified, filtering is performed using a polyethersulfone cartridge microporous filter element; after filtration, first discharging an appropriate amount of liquid medicine to eliminate interference or influence of the front-end pipeline, and then filling the remaining liquid medicine into the prefilled syringe; placing the prefilled syringe filled with liquid medicine in a ventilated dry sterilizer at 115-121°C for sterilization for 8-30 minutes to obtain the final product.

[0031] Example 1

[0032] The prescription of the prefilled atropine sulfate injection involved in this embodiment is: atropine sulfate 0.5 mg / mL, sodium chloride 9.0 mg / mL.

[0033] Prepare room temperature water for injection, sodium chloride and atropine sulfate according to the prescribed amount, dissolve sodium chloride and atropine sulfate in 95% of the prescribed amount of room temperature water for injection, and stir for 10 minutes; add 0.2% dilute sulfuric acid solution to adjust the pH to 4.0; use the remaining room temperature water for injection to make up to the full amount, stir for 5 minutes, and obtain the drug solution, at this time the pH value is 3.97; check whether the impurity content is qualified: if it is unqualified, subsequent filling and terminal sterilization will not be carried out; if it is qualified, use a polyethersulfone cartridge microporous filter element for filtration; after filtration, first discharge an appropriate amount of drug solution to eliminate interference or influence of the previous pipeline, and then fill the remaining drug solution into the prefilled syringe.

[0034] In order to verify the influence of different sterilization conditions on product impurities, this example conducted the following batches of experiments on the prefilled syringes filled with the above liquid medicine:

[0035] Batch 190810: Sterilize the prefilled syringes in a ventilated dry sterilizer at 121°C for 8 minutes;

[0036] Batch 190811: Sterilize the prefilled syringe in a ventilated dry sterilizer at 121°C for 12 minutes;

[0037] Batch 190812: Sterilize the prefilled syringes in a ventilated dry sterilizer at 121°C for 15 minutes;

[0038] Batch 190813: Sterilize the prefilled syringes in a ventilated dry sterilizer at 115°C for 30 minutes.

[0039] The prepared drug solutions of batches 190810, 190811, 190812 and 190813 were quality tested, and the results are shown in Table 1.

[0040] Table 1 Results of drug solution testing under different sterilization conditions

[0041]

[0042]

[0043]

[0044] Note: The pH value on day 0 in the table is the pH value of the drug solution after sterilization, which is higher than the pH value during preparation.

[0045] From the above data, we can see that at the sterilization temperature of 121℃, the storage stability of the product in the range of 8-15 minutes is better than that of 115℃ sterilization for 30 minutes; and there is basically no significant difference in the quality of the products sterilized at 121℃ for 8 minutes and 121℃ for 12 minutes. Combined with the investigation results, the overkilling method is selected, and the overkilling condition is reached when the sterilization time is 12 minutes. Therefore, the sterilization conditions of prefilled atropine sulfate injection are proposed to be 121℃ and 12 minutes.

[0046] Example 2

[0047] The prescription of the prefilled atropine sulfate injection involved in this embodiment is: atropine sulfate 0.5 mg / mL, sodium chloride 9.0 mg / mL.

[0048] In order to verify the effect of different solution pH on impurities during product storage, this example conducted experiments on two batches, 20191201-2 and 20191202-4:

[0049] Trial production preparation process: add 95% (19.08kg) of injection water to the preparation tank, then add the prescribed amount of atropine sulfate (batch number: 191101) and sodium chloride to the preparation tank, stir for 10 minutes to completely dissolve, adjust different pH values ​​with 0.2% sulfuric acid solution, and finally adjust the volume to the full amount (20kg) with injection water, stir for another 5 minutes, filter the liquid, and automatically fill it into a clean pre-filled injection syringe through a filling linkage machine. The pH values ​​of the two batches of liquid (20191201-2, 20191202-4) are 3.76 and 3.97 respectively. Check whether the impurity content is qualified: if it is unqualified, subsequent filling and terminal sterilization will not be carried out; if it is qualified, use polyethersulfone cartridge microporous filter element for filtration; after filtration, first discharge an appropriate amount of liquid medicine to eliminate the interference or influence of the previous pipeline, and then fill the remaining liquid medicine into the prefilled syringe; the prefilled syringe filled with liquid medicine is placed in a ventilated dry sterilizer at 121℃ for sterilization for 12 minutes to obtain the final product.

[0050] Table 2 Comparison of the test results of the drug solution with the reference preparation at pH 4.0 (allowed to fluctuate within the range of 3.8-4.2)

[0051]

[0052] Note: The pH value on day 0 in the table is the pH value of the drug solution after sterilization, which is higher than the pH value during preparation.

[0053] The results in Table 2 show that the pH of the prepared solution is 3.8 and 4.0, and the key quality attributes of the product are not lower than the reference preparation; the pH value of the homemade product after sterilization is higher than the pH when the solution is prepared; the results of the influencing factors show that the light conditions have no significant effect on the relevant substances, while under high temperature conditions, the relevant substances will increase significantly. The pH value of the prepared solution is 3.8 and 4.0, which has no significant effect on the product quality, and the impurity C and total impurities are smaller than the reference preparation.

[0054] Comparative Example 1

[0055] The product produced by Mitsubishi Pharma Corporation / Nipro was purchased, namely the reference preparation (batch number: C126): atropine sulfate 0.5 mg / mL, sodium chloride dosage 9.0 mg / mL, pH final value 4.5-5.5. The process and parameters were the same as those in Example 2.

[0056] The storage stability of the three batches of samples (190917, 190918, 190919) prepared in Example 2 was compared with the reference preparation of the comparative example (batch number: C126). The results are shown in Table 2.

[0057] Table 3 Comparison of test results of three batches of samples (190917, 190918, 190919) with the comparative reference preparations

[0058]

[0059]

[0060] The results in Table 3 show that the quality of the three batches of samples (190917, 190918, and 190919) prepared in Example 2 is better than that of the reference preparation purchased in the comparative example. When the concentration of sodium chloride is 8.5 mg / mL to 9.5 mg / mL, the osmotic pressure on day 0 is 271 to 301 mOsmol / kg, which meets the internal osmotic pressure molar concentration quality standard (should be 257 to 315 mOsmol / kg); at the same time, the influencing factor results show that when the dosage of sodium chloride is 8.5 mg / mL to 9.5 mg / mL, the relevant substances, contents, and osmotic pressure molar concentrations do not change significantly under the conditions of light and high temperature of 60°C for 10 days; It shows that the concentration of sodium chloride is 8.5 mg / mL to 9.5 mg / mL, which meets the prescription requirements. The three batches of samples prepared in Example 2 are consistent with the dosage of sodium chloride in ordinary injections, all of which are 8.5 mg / mL to 9.5 mg / mL, ensuring normal osmotic pressure (too high or too low osmotic pressure will cause harm to the human body).

[0061] Comparative Example 2

[0062] Preparation process: Weigh the prescribed amount of sodium chloride and add it to 95% of the total water volume of purified water. After stirring to dissolve, add the prescribed amount of atropine sulfate and stir until dissolved. Adjust the pH to about 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, and 6.5 with dilute sulfuric acid or sodium hydroxide solution, respectively. Make up to the full volume (150mL) with purified water, fill it into a medium-borosilicate glass ampoule and seal it after melting. Sterilize it at 121°C for 12 minutes, place the liquid at a high temperature of 60°C and light (4500±500Lx), and take samples on 0 and 10 days to detect properties, pH, content and related substances.

[0063] Table 4 Prescription process information for the pH range of the solution (1)

[0064]

[0065] Note: “ / ” means no

[0066] Table 5 Test results of drug solution at different pH values ​​(1)

[0067]

[0068]

[0069] Note: “ / ” indicates not applicable.

[0070] The results showed that the higher the pH value, the easier it was for the raw material atropine sulfate to hydrolyze, and the greater the impurity C and total impurities produced; the pH value changed greatly before and after sterilization. When the pH value of the prepared solution was between 2.5 and 5.5, the pH value increased, and when the pH value of the prepared solution was 6.5, the pH decreased after sterilization; under light conditions, the related substances and contents of the solution at different pH values ​​had no significant changes compared with those on day 0; under high temperature conditions, the related substances of the product increased significantly compared with those on day 0; when the pH value of the prepared solution was greater than 4.5, the impurity C and total impurities at high temperature for 10 days exceeded the impurity limits of the finished product quality standards (impurity C ≤ 2.0%, total impurities ≤ 3.0%).

[0071] According to the above results, the lower the pH, the lower the content of related substances. However, considering that the irritation is greater at a lower pH, the patient compliance is lower. Therefore, the pH value of the solution is limited to 3.5-4.0 based on the compliance of the product.

[0072] Comparative Example 3

[0073] Investigation of the pH range of the prepared solution 2: In order to reduce the risk of product irritation and make the pH value of the sterilized finished product closer to the reference preparation, combined with the previous study that when the pH value of the prepared solution was 4.5, the relevant substances increased significantly, so this comparative test was further refined between pH values ​​4.0 and 4.6 (the pH value of the prepared solution was set to 4.2 / 4.4 / 4.6).

[0074] Preparation process: Weigh the prescribed amount of sodium chloride and add it to 95% of the total water volume in purified water. Stir and dissolve it, then add the prescribed amount of atropine sulfate, stir until dissolved, adjust the pH to about 4.6 (batch number: 202001) / 4.4 (batch number: 202002) / 4.2 (batch number: 202003) with dilute sulfuric acid or sodium hydroxide solution, adjust the volume to the full amount (150mL) with purified water, fill it into a borosilicate glass ampoule and seal it, sterilize it at 121°C for 12 minutes, place the liquid at a high temperature of 60°C and light (4500±500Lx), and take samples at 0 days, 10 days, and 30 days to test the properties, pH, content, osmotic pressure molar concentration and related substances. And compare it with the test results of the batch (20191202-4) with the pH value of the solution adjusted to about 4.0 in the trial production study and the reference preparation C126.

[0075] Table 6 Prescription process information for the pH range of the solution (2)

[0076]

[0077] Table 7 Test results of drug solution at different pH values ​​(2)

[0078]

[0079]

[0080] The results show that when the pH value of the intermediate is within the range of 3.97-4.60, the greater the pH value, the greater the impurity C, impurity A and total impurities; the data under 0 day and light conditions show that whenever the pH value of the intermediate increases by about 0.2, the growth rate of impurity C, impurity A and total impurities is close; when the pH value of the intermediate is smaller, the growth rate of impurity C, impurity A and total impurities under high temperature conditions is also smaller, that is, the lower the pH value of the intermediate, the slower the growth rate of related substances; when the pH value of the intermediate is greater than 4.4, the impurity C and total impurities at high temperature for 30 days exceed the limit requirements of the quality standard. When the pH value of the solution is about 4.4, the related substances at high temperature for 30 days exceed the quality standard. Therefore, considering that the product quality is qualified within the validity period, the pH value of the solution is set to 3.8-4.2.

[0081] The foregoing is merely a specific embodiment of the present invention, which enables those skilled in the art to understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features claimed herein.

Claims

1. A production process for prefilled atropine sulfate injection, characterized in that: The steps include: Dissolve atropine sulfate and sodium chloride in water for injection at a temperature of <35°C according to the prescribed amount to obtain a drug solution; during the dissolution of atropine sulfate, control the pH to be 4.0±0.2; the prescription of the prefilled atropine sulfate injection solution: atropine sulfate 0.5mg / mL, sodium chloride 8.5~9.5mg / mL; the preparation method of the drug solution comprises the following steps: dissolve sodium chloride and atropine sulfate in 95% of the prescribed amount of water for injection; add dilute sulfuric acid to adjust the pH to 4.0±0.2; and use the remaining 5% of the prescribed amount of water for injection to make up the volume; Filter the liquid medicine and fill it into a prefilled syringe; Place the prefilled syringe filled with the drug solution in a ventilated dry sterilizer at 121°C for sterilization for 8 to 12 minutes to obtain the prefilled atropine sulfate injection.

2. The production process of the prefilled atropine sulfate injection according to claim 1, characterized in that: Prescription for prefilled atropine sulfate injection: atropine sulfate 0.5 mg / mL, sodium chloride 9.0 mg / mL.

3. The production process of the prefilled atropine sulfate injection according to claim 1, characterized in that: The pH value was controlled at 4.0±0.1 during the dissolution of atropine sulfate.

4. The production process of the prefilled atropine sulfate injection according to claim 3, characterized in that: During the dissolution of atropine sulfate, the pH was controlled to 4.0±0.1 by adding dilute sulfuric acid.

5. The production process of the prefilled atropine sulfate injection according to claim 4, characterized in that: The concentration of the dilute sulfuric acid is 0.2%.

6. The production process of the prefilled atropine sulfate injection according to claim 1, characterized in that: Sterilize the prefilled syringe in a ventilated dry sterilizer at 121°C for 12 minutes.

7. The production process of the prefilled atropine sulfate injection according to claim 1, characterized in that: The filtration uses a 0.22μm or 0.45μm filter element.

8. A prefilled atropine sulfate injection, characterized in that: The prefilled atropine sulfate injection is prepared by the production process of any one of claims 1 to 7.

Citation Information

Cited By

  • Atropine sulfate injection and application thereof as M choline receptor blocker

    CN117205150A